UGT1A1基因分型指导伊立替康剂量递增用于mCRC一线治疗的随机对照研究
本研究为多中心随机临床试验,比较贝伐珠单抗联合FOLFIRI方案一线治疗转移性结直肠癌时,是否依据UGT1A1基因分型进行伊立替康剂量递增的临床结局与不良事件。结果显示,基因分型指导剂量递增组在无进展生存期、总生存期、客观缓解率、疾病控制率和转移灶切除率方面均优于对照组,且≥III级不良事件无显著差异。
要点
- UGT1A1基因分型指导伊立替康剂量递增可改善mCRC一线治疗的PFS、OS和ORR。
- 剂量递增组伊立替康相对剂量强度提高1.36倍,≥III级不良事件无显著增加。
- 无论KRAS野生型或突变型,剂量递增均改善PFS。
核心结论
- mCRC患者无论KRAS基因状态如何,经UGT1A1基因分型后可耐受伊立替康剂量递增,并可能获得更优临床结局且毒性未显著增加。
研究设计与样本
- 多中心随机临床试验,研究组107例依据UGT1A1基因分型行伊立替康剂量递增,对照组106例接受常规双周FOLFIRI联合贝伐珠单抗而不做基因分型。
- 主要终点为无进展生存期,次要终点包括客观缓解率、疾病控制率、总生存期、不良事件和转移灶切除率。
主要发现
- 中位随访26.0个月(IQR 17.0-35.0个月),研究组在PFS、OS、ORR、DCR和转移灶切除率方面均优于对照组(均P<0.05)。
- 两组间≥III级不良事件无显著差异,尽管研究组伊立替康相对剂量强度提高1.36倍。
- 伊立替康剂量递增是ORR(P<0.001)和DCR(P=0.006)的独立影响因素,并改善KRAS野生型(P=0.007)和突变型(P=0.019)患者的PFS。
关键数值与推荐
- 研究组依据UGT1A1基因分型进行伊立替康剂量递增,对照组接受常规双周FOLFIRI联合贝伐珠单抗而不做基因分型。
- 研究组伊立替康相对剂量强度较对照组提高1.36倍。
临床怎么用
- 在mCRC一线贝伐珠单抗联合FOLFIRI治疗中,可考虑依据UGT1A1基因分型进行伊立替康剂量递增以改善疗效且不显著增加严重毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism plays a crucial role in the increased susceptibility of patients to irinotecan and its toxicity. This study is a multicenter, randomised clinical trial comparing the clinical outcomes and adverse events (AEs) in metastatic colorectal cancer (mCRC) patients treated with bevacizumab plus FOLFIRI with or without UGT1A1 genotyping and irinotecan dose escalation as the first-line therapy. METHODS: The control group received conventional biweekly FOLFIRI plus bevacizumab without UGT1A1 genotyping, whereas the study group received the same regimen with irinotecan dose escalation based on UGT1A1 genotyping. The primary end-point was progression-free survival (PFS), and secondary end-points were overall response rate (ORR), disease control rate (DCR), overall survival (OS), AEs and metastasectomy rate. RESULTS: Over a median follow-up of 26.0 months (IQR, 17.0-35.0 months), study group (n = 107) was superior to the control group (n = 106) in PFS, OS, ORR, DCR, and metastasectomy rate (all P < 0.05). Furthermore, there were no significant differences in AEs ≥ grade III between the two groups, even with the 1.36-fold increase in the relative dose intensity of irinotecan in the study group. Dose escalation of irinotecan, an independent factor of ORR (P < 0.001) and DCR (P = 0.006), improved PFS in mCRC patients with wild-type and mutant KRAS (P = 0.007 and P = 0.019, respectively). CONCLUSION: The current study revealed that mCRC patients, regardless of KRAS gene status, with UGT1A1 genotyping can tolerate escalated doses of irinotecan and potentially achieve a more favourable clinical outcome without significantly increased toxicities. CLINICAL TRIAL REGISTRATION: NCT02256800.
引用
- Tsai HL, Huang CW, Lin YW, et al. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST). Eur J Cancer. 2020. PMID: 32829105. doi:10.1016/j.ejca.2020.05.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。